RUNX1 is an inclusion criterion in 100 clinical trials for acute myeloid leukemia, of which 57 are open and 43 are closed. Of the trials that contain RUNX1 status and acute myeloid leukemia as inclusion criteria, 1 is early phase 1 (1 open), 30 are phase 1 (11 open), 14 are phase 1/phase 2 (11 open), 37 are phase 2 (25 open), 3 are phase 2/phase 3 (2 open), 9 are phase 3 (5 open), 1 is phase 4 (1 open), and 5 are no phase specified (1 open) [4].

RUNX1 is an inclusion criterion in 45 clinical trials for myelodysplastic syndromes, of which 32 are open and 13 are closed. Of the trials that contain RUNX1 status and myelodysplastic syndromes as inclusion criteria, 1 is early phase 1 (1 open), 14 are phase 1 (8 open), 10 are phase 1/phase 2 (10 open), 17 are phase 2 (12 open), 1 is phase 2/phase 3 (0 open), 1 is phase 3 (1 open), and 1 is no phase specified (0 open) [4].

RUNX1 is an inclusion criterion in 22 clinical trials for acute lymphoblastic leukemia, of which 16 are open and 6 are closed. Of the trials that contain RUNX1 status and acute lymphoblastic leukemia as inclusion criteria, 1 is early phase 1 (1 open), 8 are phase 1 (5 open), 1 is phase 1/phase 2 (1 open), 10 are phase 2 (8 open), 1 is phase 3 (1 open), and 1 is no phase specified (0 open) [4].

RUNX1 is an inclusion criterion in 15 clinical trials for chronic myelomonocytic leukemia, of which 11 are open and 4 are closed. Of the trials that contain RUNX1 status and chronic myelomonocytic leukemia as inclusion criteria, 5 are phase 1 (3 open), 3 are phase 1/phase 2 (3 open), and 7 are phase 2 (5 open) [4].

RUNX1 is an inclusion criterion in 14 clinical trials for chronic myeloid leukemia, of which 10 are open and 4 are closed. Of the trials that contain RUNX1 status and chronic myeloid leukemia as inclusion criteria, 6 are phase 1 (4 open), 3 are phase 1/phase 2 (3 open), 4 are phase 2 (3 open), and 1 is no phase specified (0 open) [4].

RUNX1 is an inclusion criterion in 10 clinical trials for hodgkin lymphoma, of which 6 are open and 4 are closed. Of the trials that contain RUNX1 status and hodgkin lymphoma as inclusion criteria, 5 are phase 1 (2 open), 1 is phase 1/phase 2 (1 open), 3 are phase 2 (3 open), and 1 is no phase specified (0 open) [4].

RUNX1 is an inclusion criterion in 10 clinical trials for non-hodgkin lymphoma, of which 7 are open and 3 are closed. Of the trials that contain RUNX1 status and non-hodgkin lymphoma as inclusion criteria, 1 is early phase 1 (1 open), 6 are phase 1 (3 open), and 3 are phase 2 (3 open) [4].

RUNX1 is an inclusion criterion in 9 clinical trials for acute biphenotypic leukemia, of which 5 are open and 4 are closed. Of the trials that contain RUNX1 status and acute biphenotypic leukemia as inclusion criteria, 4 are phase 1 (2 open), 1 is phase 1/phase 2 (1 open), 3 are phase 2 (2 open), and 1 is no phase specified (0 open) [4].

RUNX1 is an inclusion criterion in 9 clinical trials for multiple myeloma, of which 6 are open and 3 are closed. Of the trials that contain RUNX1 status and multiple myeloma as inclusion criteria, 1 is early phase 1 (1 open), 5 are phase 1 (3 open), 1 is phase 1/phase 2 (1 open), 1 is phase 2 (1 open), and 1 is no phase specified (0 open) [4].

RUNX1 is an inclusion criterion in 8 clinical trials for chronic lymphocytic leukemia, of which 5 are open and 3 are closed. Of the trials that contain RUNX1 status and chronic lymphocytic leukemia as inclusion criteria, 4 are phase 1 (2 open), 1 is phase 1/phase 2 (1 open), 2 are phase 2 (2 open), and 1 is phase 3 (0 open) [4].

RUNX1 is an inclusion criterion in 8 clinical trials for secondary acute myeloid leukemia, of which 8 are open and 0 are closed. Of the trials that contain RUNX1 status and secondary acute myeloid leukemia as inclusion criteria, 3 are phase 1 (3 open), 1 is phase 1/phase 2 (1 open), and 4 are phase 2 (4 open) [4].

RUNX1 is an inclusion criterion in 5 clinical trials for acute myeloid leukemia arising from previous myelodysplastic syndrome, of which 5 are open and 0 are closed. Of the trials that contain RUNX1 status and acute myeloid leukemia arising from previous myelodysplastic syndrome as inclusion criteria, 1 is phase 1 (1 open) and 4 are phase 2 (4 open) [4].

RUNX1 is an inclusion criterion in 5 clinical trials for myelodysplastic/myeloproliferative neoplasm, of which 4 are open and 1 is closed. Of the trials that contain RUNX1 status and myelodysplastic/myeloproliferative neoplasm as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 3 are phase 2 (2 open) [4].

RUNX1 is an inclusion criterion in 5 clinical trials for myeloproliferative neoplasm, of which 3 are open and 2 are closed. Of the trials that contain RUNX1 status and myeloproliferative neoplasm as inclusion criteria, 1 is phase 1 (1 open), 3 are phase 2 (2 open), and 1 is no phase specified (0 open) [4].

RUNX1 is an inclusion criterion in 5 clinical trials for refractory anemia with excess blasts, of which 3 are open and 2 are closed. Of the trials that contain RUNX1 status and refractory anemia with excess blasts as inclusion criteria, 1 is phase 1 (0 open) and 4 are phase 2 (3 open) [4].

RUNX1 is an inclusion criterion in 5 clinical trials for therapy-related acute myeloid leukemia, of which 5 are open and 0 are closed. Of the trials that contain RUNX1 status and therapy-related acute myeloid leukemia as inclusion criteria, 1 is phase 1 (1 open) and 4 are phase 2 (4 open) [4].

RUNX1 is an inclusion criterion in 4 clinical trials for double-hit lymphoma, of which 2 are open and 2 are closed. Of the trials that contain RUNX1 status and double-hit lymphoma as inclusion criteria, 1 is early phase 1 (1 open) and 3 are phase 1 (1 open) [4].

RUNX1 is an inclusion criterion in 3 clinical trials for acute leukemia, of which 1 is open and 2 are closed. Of the trials that contain RUNX1 status and acute leukemia as inclusion criteria, 1 is phase 1 (0 open), 1 is phase 2 (1 open), and 1 is no phase specified (0 open) [4].

RUNX1 is an inclusion criterion in 3 clinical trials for acute promyelocytic leukemia, of which 0 are open and 3 are closed. Of the trials that contain RUNX1 status and acute promyelocytic leukemia as inclusion criteria, 2 are phase 1 (0 open) and 1 is no phase specified (0 open) [4].

RUNX1 is an inclusion criterion in 3 clinical trials for B-cell non-hodgkin lymphoma, of which 2 are open and 1 is closed. Of the trials that contain RUNX1 status and B-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (0 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [4].

RUNX1 is an inclusion criterion in 3 clinical trials for myelodysplastic syndrome with excess blasts-2, of which 1 is open and 2 are closed. Of the trials that contain RUNX1 status and myelodysplastic syndrome with excess blasts-2 as inclusion criteria, 3 are phase 2 (1 open) [4].

RUNX1 is an inclusion criterion in 3 clinical trials for small lymphocytic lymphoma, of which 1 is open and 2 are closed. Of the trials that contain RUNX1 status and small lymphocytic lymphoma as inclusion criteria, 3 are phase 1 (1 open) [4].

RUNX1 is an inclusion criterion in 3 clinical trials for T-cell acute lymphoblastic leukemia, of which 3 are open and 0 are closed. Of the trials that contain RUNX1 status and T-cell acute lymphoblastic leukemia as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 2 are phase 2 (2 open) [4].

RUNX1 is an inclusion criterion in 2 clinical trials for acute bilineal leukemia, of which 2 are open and 0 are closed. Of the trials that contain RUNX1 status and acute bilineal leukemia as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [4].

RUNX1 is an inclusion criterion in 2 clinical trials for acute myeloid leukemia with myelodysplasia-related changes, of which 1 is open and 1 is closed. Of the trials that contain RUNX1 status and acute myeloid leukemia with myelodysplasia-related changes as inclusion criteria, 1 is phase 2 (1 open) and 1 is phase 2/phase 3 (0 open) [4].

RUNX1 is an inclusion criterion in 2 clinical trials for B-cell acute lymphoblastic leukemia, of which 2 are open and 0 are closed. Of the trials that contain RUNX1 status and B-cell acute lymphoblastic leukemia as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [4].

RUNX1 is an inclusion criterion in 2 clinical trials for chronic lymphocytic leukemia/small lymphocytic lymphoma, of which 1 is open and 1 is closed. Of the trials that contain RUNX1 status and chronic lymphocytic leukemia/small lymphocytic lymphoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is no phase specified (0 open) [4].

RUNX1 is an inclusion criterion in 2 clinical trials for diffuse large B-cell lymphoma, of which 1 is open and 1 is closed. Of the trials that contain RUNX1 status and diffuse large B-cell lymphoma as inclusion criteria, 1 is early phase 1 (1 open) and 1 is phase 1 (0 open) [4].

RUNX1 is an inclusion criterion in 2 clinical trials for juvenile myelomonocytic leukemia, of which 1 is open and 1 is closed. Of the trials that contain RUNX1 status and juvenile myelomonocytic leukemia as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 2 (1 open) [4].

RUNX1 is an inclusion criterion in 2 clinical trials for lymphoma, of which 1 is open and 1 is closed. Of the trials that contain RUNX1 status and lymphoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 2 (1 open) [4].

RUNX1 is an inclusion criterion in 2 clinical trials for mantle cell lymphoma, of which 1 is open and 1 is closed. Of the trials that contain RUNX1 status and mantle cell lymphoma as inclusion criteria, 1 is early phase 1 (1 open) and 1 is no phase specified (0 open) [4].

RUNX1 is an inclusion criterion in 2 clinical trials for mixed phenotype acute leukemia, of which 2 are open and 0 are closed. Of the trials that contain RUNX1 status and mixed phenotype acute leukemia as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [4].

RUNX1 is an inclusion criterion in 2 clinical trials for myelofibrosis, of which 1 is open and 1 is closed. Of the trials that contain RUNX1 status and myelofibrosis as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 2 (1 open) [4].

RUNX1 is an inclusion criterion in 2 clinical trials for myeloid neoplasm, of which 2 are open and 0 are closed. Of the trials that contain RUNX1 status and myeloid neoplasm as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [4].

RUNX1 is an inclusion criterion in 2 clinical trials for refractory anemia, of which 1 is open and 1 is closed. Of the trials that contain RUNX1 status and refractory anemia as inclusion criteria, 2 are phase 2 (1 open) [4].

RUNX1 is an inclusion criterion in 2 clinical trials for secondary myelodysplastic syndrome, of which 1 is open and 1 is closed. Of the trials that contain RUNX1 status and secondary myelodysplastic syndrome as inclusion criteria, 2 are phase 2 (1 open) [4].

RUNX1 is an inclusion criterion in 2 clinical trials for therapy-related myelodysplastic syndrome, of which 2 are open and 0 are closed. Of the trials that contain RUNX1 status and therapy-related myelodysplastic syndrome as inclusion criteria, 2 are phase 1 (2 open) [4].

RUNX1 is an inclusion criterion in 1 clinical trial for acute erythroid leukemia, of which 1 is open and 0 are closed. Of the trial that contains RUNX1 status and acute erythroid leukemia as inclusion criteria, 1 is phase 2 (1 open) [4].

RUNX1 is an inclusion criterion in 1 clinical trial for acute megakaryoblastic leukemia, of which 1 is open and 0 are closed. Of the trial that contains RUNX1 status and acute megakaryoblastic leukemia as inclusion criteria, 1 is phase 2 (1 open) [4].

RUNX1 is an inclusion criterion in 1 clinical trial for acute myeloid leukemia with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11, of which 1 is open and 0 are closed. Of the trial that contains RUNX1 status and acute myeloid leukemia with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11 as inclusion criteria, 1 is phase 4 (1 open) [4].

RUNX1 is an inclusion criterion in 1 clinical trial for acute myeloid leukemia with t(8;21); (q22; q22.1); RUNX1-RUNX1T1, of which 1 is open and 0 are closed. Of the trial that contains RUNX1 status and acute myeloid leukemia with t(8;21); (q22; q22.1); RUNX1-RUNX1T1 as inclusion criteria, 1 is phase 4 (1 open) [4].

RUNX1 is an inclusion criterion in 1 clinical trial for acute undifferentiated leukemia, of which 1 is open and 0 are closed. Of the trial that contains RUNX1 status and acute undifferentiated leukemia as inclusion criteria, 1 is phase 2 (1 open) [4].

RUNX1 is an inclusion criterion in 1 clinical trial for adult T-cell leukemia/lymphoma, of which 0 are open and 1 is closed. Of the trial that contains RUNX1 status and adult T-cell leukemia/lymphoma as inclusion criteria, 1 is no phase specified (0 open) [4].

RUNX1 is an inclusion criterion in 1 clinical trial for anaplastic astrocytoma, of which 0 are open and 1 is closed. Of the trial that contains RUNX1 status and anaplastic astrocytoma as inclusion criteria, 1 is phase 1 (0 open) [4].

RUNX1 is an inclusion criterion in 1 clinical trial for anaplastic large cell lymphoma, of which 0 are open and 1 is closed. Of the trial that contains RUNX1 status and anaplastic large cell lymphoma as inclusion criteria, 1 is no phase specified (0 open) [4].

RUNX1 is an inclusion criterion in 1 clinical trial for aplastic anemia, of which 1 is open and 0 are closed. Of the trial that contains RUNX1 status and aplastic anemia as inclusion criteria, 1 is phase 1 (1 open) [4].

RUNX1 is an inclusion criterion in 1 clinical trial for atypical chronic myeloid leukemia, BCR-ABL1 negative, of which 0 are open and 1 is closed. Of the trial that contains RUNX1 status and atypical chronic myeloid leukemia, BCR-ABL1 negative as inclusion criteria, 1 is no phase specified (0 open) [4].

RUNX1 is an inclusion criterion in 1 clinical trial for bladder carcinoma, of which 0 are open and 1 is closed. Of the trial that contains RUNX1 status and bladder carcinoma as inclusion criteria, 1 is phase 1 (0 open) [4].

RUNX1 is an inclusion criterion in 1 clinical trial for breast carcinoma, of which 0 are open and 1 is closed. Of the trial that contains RUNX1 status and breast carcinoma as inclusion criteria, 1 is phase 1 (0 open) [4].

RUNX1 is an inclusion criterion in 1 clinical trial for Burkitt lymphoma, of which 0 are open and 1 is closed. Of the trial that contains RUNX1 status and Burkitt lymphoma as inclusion criteria, 1 is no phase specified (0 open) [4].

RUNX1 is an inclusion criterion in 1 clinical trial for chronic myelomonocytic leukemia-0, of which 1 is open and 0 are closed. Of the trial that contains RUNX1 status and chronic myelomonocytic leukemia-0 as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

RUNX1 is an inclusion criterion in 1 clinical trial for chronic myelomonocytic leukemia-1, of which 1 is open and 0 are closed. Of the trial that contains RUNX1 status and chronic myelomonocytic leukemia-1 as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

RUNX1 is an inclusion criterion in 1 clinical trial for chronic myelomonocytic leukemia-2, of which 1 is open and 0 are closed. Of the trial that contains RUNX1 status and chronic myelomonocytic leukemia-2 as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

RUNX1 is an inclusion criterion in 1 clinical trial for colorectal carcinoma, of which 0 are open and 1 is closed. Of the trial that contains RUNX1 status and colorectal carcinoma as inclusion criteria, 1 is phase 1 (0 open) [4].

RUNX1 is an inclusion criterion in 1 clinical trial for core binding factor acute myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains RUNX1 status and core binding factor acute myeloid leukemia as inclusion criteria, 1 is phase 3 (1 open) [4].

RUNX1 is an inclusion criterion in 1 clinical trial for follicular lymphoma, of which 0 are open and 1 is closed. Of the trial that contains RUNX1 status and follicular lymphoma as inclusion criteria, 1 is no phase specified (0 open) [4].

RUNX1 is an inclusion criterion in 1 clinical trial for glioblastoma, of which 0 are open and 1 is closed. Of the trial that contains RUNX1 status and glioblastoma as inclusion criteria, 1 is phase 1 (0 open) [4].

RUNX1 is an inclusion criterion in 1 clinical trial for head and neck carcinoma, of which 0 are open and 1 is closed. Of the trial that contains RUNX1 status and head and neck carcinoma as inclusion criteria, 1 is phase 1 (0 open) [4].

RUNX1 is an inclusion criterion in 1 clinical trial for histiocytic and dendritic cell neoplasm, of which 1 is open and 0 are closed. Of the trial that contains RUNX1 status and histiocytic and dendritic cell neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

RUNX1 is an inclusion criterion in 1 clinical trial for indolent non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains RUNX1 status and indolent non-hodgkin lymphoma as inclusion criteria, 1 is phase 2 (1 open) [4].

RUNX1 is an inclusion criterion in 1 clinical trial for leukemia, of which 1 is open and 0 are closed. Of the trial that contains RUNX1 status and leukemia as inclusion criteria, 1 is phase 2 (1 open) [4].

RUNX1 is an inclusion criterion in 1 clinical trial for lymphoblastic lymphoma, of which 1 is open and 0 are closed. Of the trial that contains RUNX1 status and lymphoblastic lymphoma as inclusion criteria, 1 is phase 1 (1 open) [4].

RUNX1 is an inclusion criterion in 1 clinical trial for lymphoplasmacytic lymphoma, of which 0 are open and 1 is closed. Of the trial that contains RUNX1 status and lymphoplasmacytic lymphoma as inclusion criteria, 1 is no phase specified (0 open) [4].

RUNX1 is an inclusion criterion in 1 clinical trial for malignant solid tumor, of which 0 are open and 1 is closed. Of the trial that contains RUNX1 status and malignant solid tumor as inclusion criteria, 1 is phase 1 (0 open) [4].

RUNX1 is an inclusion criterion in 1 clinical trial for marginal zone lymphoma, of which 0 are open and 1 is closed. Of the trial that contains RUNX1 status and marginal zone lymphoma as inclusion criteria, 1 is no phase specified (0 open) [4].

RUNX1 is an inclusion criterion in 1 clinical trial for mature B-cell lymphoma/leukemia, of which 0 are open and 1 is closed. Of the trial that contains RUNX1 status and mature B-cell lymphoma/leukemia as inclusion criteria, 1 is phase 1 (0 open) [4].

RUNX1 is an inclusion criterion in 1 clinical trial for mature T-cell and NK-cell lymphoma/leukemia, of which 0 are open and 1 is closed. Of the trial that contains RUNX1 status and mature T-cell and NK-cell lymphoma/leukemia as inclusion criteria, 1 is no phase specified (0 open) [4].

RUNX1 is an inclusion criterion in 1 clinical trial for mature T-cell and NK-cell neoplasm, of which 1 is open and 0 are closed. Of the trial that contains RUNX1 status and mature T-cell and NK-cell neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

RUNX1 is an inclusion criterion in 1 clinical trial for mediastinal large B-cell lymphoma, of which 0 are open and 1 is closed. Of the trial that contains RUNX1 status and mediastinal large B-cell lymphoma as inclusion criteria, 1 is phase 1 (0 open) [4].

RUNX1 is an inclusion criterion in 1 clinical trial for melanoma, of which 0 are open and 1 is closed. Of the trial that contains RUNX1 status and melanoma as inclusion criteria, 1 is phase 1 (0 open) [4].

RUNX1 is an inclusion criterion in 1 clinical trial for myelodysplastic/myeloproliferative neoplasm, unclassifiable, of which 1 is open and 0 are closed. Of the trial that contains RUNX1 status and myelodysplastic/myeloproliferative neoplasm, unclassifiable as inclusion criteria, 1 is phase 1 (1 open) [4].

RUNX1 is an inclusion criterion in 1 clinical trial for myeloid sarcoma, of which 1 is open and 0 are closed. Of the trial that contains RUNX1 status and myeloid sarcoma as inclusion criteria, 1 is phase 2 (1 open) [4].

RUNX1 is an inclusion criterion in 1 clinical trial for natural killer cell lymphoblastic leukemia/lymphoma, of which 1 is open and 0 are closed. Of the trial that contains RUNX1 status and natural killer cell lymphoblastic leukemia/lymphoma as inclusion criteria, 1 is phase 2 (1 open) [4].

RUNX1 is an inclusion criterion in 1 clinical trial for non-small cell lung carcinoma, of which 0 are open and 1 is closed. Of the trial that contains RUNX1 status and non-small cell lung carcinoma as inclusion criteria, 1 is phase 1 (0 open) [4].

RUNX1 is an inclusion criterion in 1 clinical trial for ovarian carcinoma, of which 0 are open and 1 is closed. Of the trial that contains RUNX1 status and ovarian carcinoma as inclusion criteria, 1 is phase 1 (0 open) [4].

RUNX1 is an inclusion criterion in 1 clinical trial for pancreatic carcinoma, of which 0 are open and 1 is closed. Of the trial that contains RUNX1 status and pancreatic carcinoma as inclusion criteria, 1 is phase 1 (0 open) [4].

RUNX1 is an inclusion criterion in 1 clinical trial for peripheral T-cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains RUNX1 status and peripheral T-cell lymphoma as inclusion criteria, 1 is early phase 1 (1 open) [4].

RUNX1 is an inclusion criterion in 1 clinical trial for polycythemia vera, of which 1 is open and 0 are closed. Of the trial that contains RUNX1 status and polycythemia vera as inclusion criteria, 1 is phase 2 (1 open) [4].

RUNX1 is an inclusion criterion in 1 clinical trial for primary myelofibrosis, of which 1 is open and 0 are closed. Of the trial that contains RUNX1 status and primary myelofibrosis as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

RUNX1 is an inclusion criterion in 1 clinical trial for prolymphocytic leukemia, of which 0 are open and 1 is closed. Of the trial that contains RUNX1 status and prolymphocytic leukemia as inclusion criteria, 1 is no phase specified (0 open) [4].

RUNX1 is an inclusion criterion in 1 clinical trial for sarcoma, of which 0 are open and 1 is closed. Of the trial that contains RUNX1 status and sarcoma as inclusion criteria, 1 is phase 1 (0 open) [4].

RUNX1 is an inclusion criterion in 1 clinical trial for small lymphocytic leukemia, of which 0 are open and 1 is closed. Of the trial that contains RUNX1 status and small lymphocytic leukemia as inclusion criteria, 1 is phase 1 (0 open) [4].

RUNX1 is an inclusion criterion in 1 clinical trial for T-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains RUNX1 status and T-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 2 (1 open) [4].

RUNX1 is an inclusion criterion in 1 clinical trial for therapy-related chronic myelomonocytic leukemia, of which 1 is open and 0 are closed. Of the trial that contains RUNX1 status and therapy-related chronic myelomonocytic leukemia as inclusion criteria, 1 is phase 1 (1 open) [4].

RUNX1 is an inclusion criterion in 1 clinical trial for waldenstrom macroglobulinemia, of which 1 is open and 0 are closed. Of the trial that contains RUNX1 status and waldenstrom macroglobulinemia as inclusion criteria, 1 is phase 2 (1 open) [4].